

WATSON PHARMACEUTICALS INC  
Form 4  
September 04, 2007

**FORM 4** UNITED STATES SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549

OMB APPROVAL

OMB Number: 3235-0287  
Expires: January 31, 2005  
Estimated average burden hours per response... 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

**STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES**

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person \*  
**BISARO PAUL**

2. Issuer Name and Ticker or Trading Symbol  
**WATSON PHARMACEUTICALS INC [WPI]**

5. Relationship of Reporting Person(s) to Issuer

(Check all applicable)

(Last) (First) (Middle)  
**360 MOUNT KEMBLE AVENUE**  
(Street)

3. Date of Earliest Transaction (Month/Day/Year)  
**09/04/2007**

Director  10% Owner  
 Officer (give title below)  Other (specify below)  
**President & CEO**

**MORRISTOWN, NJ 07960**

(City) (State) (Zip)

4. If Amendment, Date Original Filed(Month/Day/Year)

6. Individual or Joint/Group Filing(Check Applicable Line)  
 Form filed by One Reporting Person  
 Form filed by More than One Reporting Person

**Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned**

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)	4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock, par value \$0.0033	09/04/2007		A		42,600 (1)	A	\$ 0 42,600

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.**

SEC 1474  
(9-02)

**Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned**  
(e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)	5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	6. Date Exercisable and Expiration Date (Month/Day/Year)	7. Title and Amount of Underlying Security (Instr. 3 and 4)		
				Code	V (A) (D)	Date Exercisable	Expiration Date	Title	Am Nur Sha
Non-Qualified Options to Purchase Common Stock <u>(2)</u>	\$ 30.66	09/04/2007		A	127,200	<u>(3)</u>	09/04/2017	Common Stock, par value \$0.0033	12
Non-Qualified Options to Purchase Common Stock <u>(4)</u>	\$ 30.66	09/04/2007		A	400,000	<u>(5)</u>	09/04/2017	Common Stock, par value \$0.0033	40

## Reporting Owners

Reporting Owner Name / Address	Relationships			
	Director	10% Owner	Officer	Other
BISARO PAUL 360 MOUNT KEMBLE AVENUE MORRISTOWN, NJ 07960	X		President & CEO	

## Signatures

Paul M. Bisaro 09/04/2007

    Signature of  
Reporting Person

Date

## Explanation of Responses:

- \* If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).
  - \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- The restricted stock was issued pursuant to the Second Amendment and Restatement of the 2001 Incentive Award Plan of Watson Pharmaceuticals, Inc., and 50% of the shares shall vest on the second anniversary of the transaction date, and the remaining 50% of the shares shall vest on the fourth anniversary of the transaction date.
- (1) The options are to be incentive stock options to the extent permitted by law, and thereafter to be non-statutory stock options.
  - (2) The options will vest and become exercisable with respect to 25% of the shares subject thereto on each anniversary of the transaction date.
  - (3) The options are to be incentive stock options to the extent permitted by law, and thereafter to be non-statutory stock options.
  - (4) The options will vest in three (3) substantially equal annual installments commencing on the third anniversary of the transaction date.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure.

Edgar Filing: WATSON PHARMACEUTICALS INC - Form 4

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.